Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.87 |
| ▸ | USP2 | O75604 | 3/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.87 |
| ▸ | RECQL | P46063 | 2/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | LCK | P06239 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | YARS1 | P54577 | 2/20 | 0.61 |
| ▸ | KDM6B | O15054 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL4120877 | 1.00 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL23853065 | 1.00 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL27971720 | 1.00 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL23069646 | 1.00 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL8579019 | 0.95 | SLC7A5 (0.79) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL8579024 | 0.95 | SLC7A5 (0.79) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL8599507 | 0.94 | SLC7A5 (0.77) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL116907 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL20582239 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL11000382 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-12018304-B2 | Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4253525-A2 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4247937-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230203551-A1 | Noscapinoid-producing Microbes and Methods of Making and Using the Same | HERCULES CAPITAL, INC., AS AGENT | 2023-06-29 | — | — | US | disclosed |
| WO-2022109194-A9 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-5932439-A | GENETICALLY ENGINEERED BACTERIAL STRAIN WITH REDUCED EXPRESSION OF CATECHOL AND INCREASED EXPRESSION OF GENES ASSOCIATED WITH PYRIMIDINE BIOSYNTHESIS; SYNTHESIS OF HETEROLOGOUS POLYPEPTIDES SUCH AS INSULIN AND SOMATOTROPIN | MONSANTO COMAPNY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5856308-A | POLYPEPTIDES; WOUND HEALING AGENTS | HAEMACURE CORPORATION (CA) | 1999-01-05 | — | — | US | disclosed |
| US-5637756-A | TREATMENT OF SKIN DISORDERS, BLEACHING OF PIGMENTED SPOTS, COSMETICS | L'OREAL (FR) | 1997-06-10 | — | — | US | disclosed |
| US-5618519-A | USEFUL FOR PROVIDING A NATURALLY-APPEARING TAN TO MAMMALIAN SKIN AND HAIR; PRODUCED BY POLYMERIZING DIHYDROXYINDOLE CARBOXYLIC ACID WITH AERATION | YALE UNIVERSITY (US) | 1997-04-08 | — | — | US | disclosed |
| US-5474905-A | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens | RESEARCH CORPORATION TECHNOLOGIES (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995014712-A1 | STREPTOCOCCUS PNEUMONIAE HEMIN/HEMOGLOBIN-BINDING ANTIGENS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0547065-A4 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0547065-A1 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | Biosource Technologies, Inc. (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5122461-A | Reacting monophenolic compounds with oxygen in presence of monophenol monooxygenase and metal ions; product stabilized by complexing with metals; increasing DOPA yield | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1992-06-16 | — | — | US | disclosed |
| WO-1992000373-A1 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | BIOSOURCE GENETICS CORPORATION (CA) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203551-A1 | Noscapinoid-producing Microbes and Methods of Making and Using the Same | NOS2, NISCH, NOS1 | SLC7A5 757/4885USP2 2888/4885PTGS1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.